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et al.: On the Job

Changing Lives Through Research

On the Job
When Dr. Yeo left Johns Hopkins in October
of 2005 to lead the Department of Surgery at
Jefferson, he had big plans. Over the last ten
years, the improvements have been dramatic
across the board thanks to the support and
contributions of five faculty members he
selected to serve as vice chairs:

In the Curtis Building laboratories, Drs. Jordan Winter, Jonathan Brody, and Suzan Lanza-Jacoby join forces to
disrupt the energy supply of pancreatic cancer cells.

Dr. Lanza-Jacoby Secures
Two-Year Grant from NIH
National Cancer Institute
Team to study novel compound that
blocks glucose transporter protein
crucial to cancer cell growth
Jefferson researcher Susan LanzaJacoby, PhD, has been awarded
a two-year grant by the National
Institutes of Health (NIH) National
Cancer Institute (NCI) to study the use
of energy restriction mimetics to slow
the progression of pancreatic cancer,
reduce the incidence of pancreatic
ductal adenocarcinoma and improve
the survival rate. Dr. Jacoby formally
initiated the project in September
with Jonathan Brody, PhD, Director
of Surgical Research and Co-director
of the Jefferson Pancreas, Biliary and
Related Cancer Center, and Jordan
Winter, MD, FACS, Associate Professor,
Sidney Kimmel Medical College at
Thomas Jefferson University.
As Dr. Jacoby explains, cancer cells
require a lot of glucose, or energy,
to grow. Energy restriction mimetics
is the process of limiting glucose to
hinder cancer cell growth. In one of
her previous studies, Dr. Jacoby found
that cutting the caloric intake of mice
by 25 percent reduced the number
of animals who developed pancreatic
cancer. For this new study, the team
will test whether and to what extent a
new compound, known as CG5, has
the same effect. They are collaborating
with the Ohio State University
medicinal chemist, Dr. Ching-shih
Chen, who developed the compound.
While Jefferson’s is the first study to
focus on CG5 for pancreatic cancer,

previous studies have found that the
compound inhibits the growth of
colorectal and prostate cancer cells
in mice.

Jonathan Brody, PhD, Vice Chair for
Research, supervises and facilitates
research activities in the Department. To
support and publicize research initiatives,
Dr. Brody manages a pilot grant program
for the surgical faculty, a research seminar
series, and a bi-annual resident research
symposium. He works with other faculty
to strengthen the research infrastructure,
encourage faculty interests, increase
investigator initiated clinical trials, expand
the departmental grant portfolio, and
establish a clinically useful biobank.
Ernest Rosato, MD, Vice Chair for Clinical
Affairs, is responsible for supervising
many elements within the clinical domain
including faculty roles, the maintenance
of surgical outcomes, safety and volume.
Dr. Rosato works closely with Dr. Yeo to
develop strategies for clinical growth, faculty
recruitment and retention, and program
development within the Department and
across Jefferson Health.
Karen Chojnacki, MD, Vice Chair for
Education, is responsible for facilitating
the educational mission of the Department,
including overseeing the educational
program for 40 surgical residents. In her role
as Program Director, Dr. Chojnacki develops
the resident lecture series, implements
rotation and call schedules, manages
resident recruitment, and maintains program

compliance with the ACGME surgical
residency requirements. Dr. Chojnacki and
her education team work continuously to
maintain the surgical residency’s status as
a top tier program. In conjunction with the
Dean’s office, she facilitates educational
opportunities for faculty development
including seminars and workshops on
teaching methods.
Scott Cowan, MD, Vice Chair for Quality, is
responsible for overseeing the development,
implementation and tracking of quality and
safety initiatives within the Department.
As Surgeon Champion for the American
College of Surgeons National Surgical
Quality Improvement Program (ACS
NSQIP®) at Jefferson and Vice President of
the Pennsylvania NSQIP Consortium, Dr.
Cowan is establishing Jefferson as a leader
in promoting surgical quality and safety. The
Department’s new Quality Based Initiative in
Resident Training (QBIRT) program (led by
surgical residents with Dr. Cowan’s guidance)
has already demonstrated a direct and
significant positive impact on patient care.
Francesco Palazzo, MD, Vice Chair at
Methodist, is responsible for all professional,
administrative, and research activities within
the Department of Surgery at Methodist
Hospital in South Philadelphia. Dr. Palazzo
continually assesses performance and elicits
improvements to the care and services
provided at Methodist. Under his leadership,
two Methodist “white papers” have been
completed. Dr. Palazzo also teaches third
and fourth year students from Sidney
Kimmel Medical College and Jefferson
surgery residents during their Methodist
Hospital rotation.

“By inhibiting glucose metabolism, the
compound acts, in a sense, like food
or calorie restriction,” she says. “More
specifically, CG5 inhibits the glucose
transporter 1 protein, or GLUT1, which
is necessary for glucose to get in the
cell and be broken down into energy.
The hope is that by inhibiting GLUT1,
CG5 will ‘starve’ pancreatic tumors.”

While Jefferson’s is
the first study to focus
on CG5 for pancreatic
cancer, previous studies
have found that the
compound inhibits the
growth of colorectal
and prostate cancer
cells in mice.
This early-stage study will use
transgenic mice in which every cell
contains additional foreign DNA.
This extra DNA enables researchers
to study gene function or regulation
and to model human diseases.
Researchers will be analyzing whether
and how much the compound
inhibits carbohydrate metabolism and
transport and utilization of glucose.

Jonathan Brody, PhD, Ernest Rosato, MD, Karen Chojnacki, MD, Charles Yeo, MD, Scott Cowan, MD,
Francesco Palazzo, MD

“We will see if we can inhibit the
growth of what we call precursor cancerous lesions – advanced lesions in
the pancreas that progress to pancreatic cancer,” Dr. Brody explains. “We’ll
also be exploring how the compound
affects the RNA binding protein, HuR,
which we’ve been studying in our
laboratory for a number of years.
“In other studies, we’ve found that
inhibiting HuR makes pancreatic
cancer cells more sensitive to
chemotherapy. We hypothesize
that the CG5 compound may also
inhibit HuR, thereby yielding better
chemotherapy outcomes.”

Dr. Jacoby emphasizes that this is a
very early-stage, mouse-model study,
and it will take extensive research,
including additional animal studies and
a toxicity profile, to determine whether
or not the CG5 compound can be
safely used in humans.
“It’s too soon to translate this for
humans,” she notes. “Ultimately,
though, the goal is to develop a drug
that will alter metabolism to reduce
the incidence and progression of
pancreatic cancer – without requiring
people to slash their caloric intake.”
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